Low-Dose Oral Minoxidil for Treatment of Androgenetic Alopecia and Telogen Effluvium in a Pediatric Population: A Descriptive Study
April 2022
in “
Journal of The American Academy of Dermatology
”
TLDR Low-dose oral minoxidil improved hair growth in most pediatric patients with mild side effects.
This study retrospectively reviewed the use of low-dose oral minoxidil (LDOM) in 45 pediatric patients (mean age 16 years) with androgenetic alopecia (87%) or telogen effluvium (13%) over a 2-year period. The treatment showed clinical improvement in hair density in 80% of patients, with hair loss stabilization in the remaining 20%. Adverse effects were mild and occurred in 25% of patients, with facial hypertrichosis being the most common. The study suggests that LDOM is a promising nonhormonal treatment option for pediatric hair disorders, though further research is needed to confirm its safety and efficacy.